Skip to content

Percutaneous Radiofrequency ablation for Pulmonary Metastasis from Colorectal Cancer: Phase II Clinical Trial

Percutaneous Radiofrequency ablation for Pulmonary Metastasis from Colorectal Cancer: Phase II Clinical Trial - SCIRO-1401 study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000014391
Enrollment
45
Registered
2014-06-27
Start date
2014-07-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary metastasis from colorectal cancer

Interventions

Sponsors

Department of Radiology, Okayama University Medical School
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) (a)Colorectal cancer patients in whom primary lesion is controlled. (b)Patients who have pulmonary metastasis diagnosed clinically and radiologically. (c)Absence of viable extrapulmonary metastasis. (d)All of the pulmonary metastases is considered to be treatable with RFA. 2)Pulmonary metastases with the number of less than 6 and long axis diameter of smaller than 3.0cm. 3)No disfunction of major organs.

Exclusion criteria

Exclusion criteria: 1)Lack of safe needle insertion path. 2)RFA is considered to be de hazardous because of critical organs close to the target lesion. 3)Presence of sever comorbidities. 4)Presence of uncontrolled other malignant diseases. 5)Presence of peritoneal dissemination and/or malignant ascites. 6)Fever higher than 38-Celsius degree. 7)Severe impairment of contralateral pulmonary function. 8)Presence of pulmonary hypertension. 9)Presence of interstitial pneumonia. 10)Usage of anticoagulants and antiplatelet agents. 11)Pregnant patients. 12)Patients who are considered to be unsuitable for inclusion by physicians due to other reasons.

Design outcomes

Primary

MeasureTime frame
3-year overall survival

Secondary

MeasureTime frame
1- and 5-year overall survival, Adverse events, Local tumor control, Cause-specific survival, Relapse-free survival

Countries

Japan

Contacts

Public ContactYusuke Matsui

Okayama University Medical School Department of Radiology

wckyh140@yahoo.co.jp086-235-7313

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026